Literature DB >> 34527553

LRP6 as a biomarker of poor prognosis of breast cancer.

Yunke Zhang1, Chengchang Shu1, Yusufu Maimaiti1,2, Shuntao Wang1, Chong Lu1, Jing Zhou1,3.   

Abstract

BACKGROUND: Recently, low-density lipoprotein receptor (LDLR)-related protein 6 (LRP6) has been the focus of molecular targeted therapy for breast cancer; however, its role in breast cancer is still controversial. The purpose of this study was to investigate the effect of LRP6 overexpression on the prognosis of breast cancer.
METHODS: We used immunohistochemistry to detect the expression of LRP6 via tissue microarrays in breast cancer samples, Chi-square test analyze the relationship between LRP6 expression and clinicopathological features of breast cancer, the Kaplan-Meier method to perform survival analysis, and the Cox proportional hazards regression model to explore the potential risk factors of breast cancer. The role of LRP6 in the proliferation, invasion, and metastasis of breast cancer was studied by colony formation, Transwell migration and invasion assay and scratch assay. The tumor-bearing model of LRP6 knockdown was established using MCF-7 cells, and corresponding negative control was set up to observe the growth rate of the two models.
RESULTS: High expression of LRP6 was observed in 89 out of 150 (59.3%) breast cancer cases, as detected by microarray of breast cancer tissue. Chi-square tests showed no significant correlation between LRP6 expression and tumor size, lymph node staging, or mitosis. Survival analysis showed that the overall survival rate of tumor patients with high LRP6 expression was significantly lower than that of patients with low LRP6 expression. Univariate and multivariate regression analyses revealed that LRP6 was an independent risk factor for breast cancer and was negatively correlated with the prognosis of breast cancer. Compared with the control group, small interference RNA (si-RNA) knockdown of LRP6 significantly reduced the clonogenic rate as well as the migration and invasion abilities of MCF-7 cells. In the scratch experiment, the wound healing ability of the LRP6 knockdown was significantly weaker than that of the control group. There were significant differences in tumor growth weight and volume between lentivirus transfected LRP6 knockdown MCF-7 cell line and control MCF-7 cell line in nude mice.
CONCLUSIONS: LRP6 could be a useful biomarker of poor prognosis of breast cancer, as it plays an important role in tumor growth, migration, and invasion. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Low-density lipoprotein receptor-related protein 6 (low-density LRP6); biomarker; breast cancer; prognosis

Year:  2021        PMID: 34527553      PMCID: PMC8411082          DOI: 10.21037/gs-21-194

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  26 in total

1.  The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.

Authors:  José Manuel González-Sancho; Oscar Aguilera; José Miguel García; Natalia Pendás-Franco; Cristina Peña; Santiago Cal; Antonio García de Herreros; Félix Bonilla; Alberto Muñoz
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

2.  Dickkopf-1 expression is down-regulated during the colorectal adenoma-carcinoma sequence and correlates with reduced microvessel density and VEGF expression.

Authors:  Zhiyong Liu; Baocun Sun; Lisha Qi; Yixian Li; Xiulan Zhao; Danfang Zhang; Yanhui Zhang
Journal:  Histopathology       Date:  2015-02-12       Impact factor: 5.087

3.  RETRACTED: lncRNA PEG10 promotes cell survival, invasion and migration by sponging miR-134 in human bladder cancer.

Authors:  Fuquan Jiang; Wenqian Qi; Yao Wang; Weihua Wang; Li Fan
Journal:  Biomed Pharmacother       Date:  2019-04-04       Impact factor: 6.529

4.  Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.

Authors:  Wenyan Lu; Cuihong Lin; Michael J Roberts; William R Waud; Gary A Piazza; Yonghe Li
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

5.  Dephosphorylated cofilin expression is associated with poor prognosis in cases of human breast cancer: a tissue microarray analysis.

Authors:  Yusufu Maimaiti; Zeming Liu; Jie Tan; Kelimu Abudureyimu; Bangxing Huang; Chunping Liu; Yawen Guo; Changwen Wang; Xiu Nie; Jing Zhou; Tao Huang
Journal:  Onco Targets Ther       Date:  2016-10-19       Impact factor: 4.147

6.  Maintenance of stemness is associated with the interation of LRP6 and heparin-binding protein CCN2 autocrined by hepatocellular carcinoma.

Authors:  Qingan Jia; Yang Bu; Zhiming Wang; Bendong Chen; Qiangbo Zhang; Songning Yu; Qingguang Liu
Journal:  J Exp Clin Cancer Res       Date:  2017-09-04

7.  Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).

Authors:  Ting Zhou; Jianhua Zhan; Wenfeng Fang; Yuanyuan Zhao; Yunpeng Yang; Xue Hou; Zhonghan Zhang; Xiaobo He; Yaxiong Zhang; Yan Huang; Li Zhang
Journal:  BMC Cancer       Date:  2017-04-14       Impact factor: 4.430

8.  Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer.

Authors:  Sushil Kumar; Ratnesh Kumar Srivastav; David W Wilkes; Taylor Ross; Sabrina Kim; Jules Kowalski; Srinivas Chatla; Qing Zhang; Anupma Nayak; Manti Guha; Serge Y Fuchs; Christoforos Thomas; Rumela Chakrabarti
Journal:  Oncogene       Date:  2018-11-15       Impact factor: 9.867

Review 9.  The Roles of Low-Density Lipoprotein Receptor-Related Proteins 5, 6, and 8 in Cancer: A Review.

Authors:  Zulaika Roslan; Mudiana Muhamad; Lakshmi Selvaratnam; Sharaniza Ab-Rahim
Journal:  J Oncol       Date:  2019-03-26       Impact factor: 4.375

10.  LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS.

Authors:  Yao Yuan; Xiaoyan Xie; Yuchen Jiang; Zihao Wei; Peiqi Wang; Fangman Chen; Xinyi Li; Chongkui Sun; Hang Zhao; Xin Zeng; Lu Jiang; Yu Zhou; Hongxia Dan; Mingye Feng; Rui Liu; Zhiyong Wang; Qianming Chen
Journal:  Cell Death Dis       Date:  2017-09-07       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.